Diffusion’s Chief Medical Officer Dr. Chris Galloway provides an overview of the ILD-DLCO Trial, the third in a trio of Oxygenation Trials that will inform late-phase programs and clinical indications for lead drug candidate TSC.

Chief Medical Officer Dr. Chris Galloway previews Diffusion’s Altitude Trial, the second in a trio of Oxygenation Trials that will collectively inform late phase programs and the clinical development plan for lead drug candidate TSC.

Dr. Chris Galloway, Chief Medical Officer of Diffusion, explains the TCOM Trial design, top-line results, and the relevancy of this first of three Oxygenation Trials that together will inform late-phase programs and clinical indications for lead drug candidate TSC.

In this episode, Diffusion Pharmaceuticals CEO Robert Cobuzzi, Jr., PhD discusses cellular oxygen deficiency, a condition known as hypoxia, outlines the company’s development plan, and highlights potential future applications for a small molecule therapeutic with a novel mechanism-of-action that enhances oxygen diffusion.

Hypoxia, a potentially fatal shortage of oxygen in body tissue, is a serious and potentially fatal medical condition. In Fueling Life, a new podcast from Diffusion Pharmaceuticals, we’ll discuss how and why hypoxia occurs, and explore how Diffusion Pharmaceuticals’ lead product candidate, trans sodium crocetinate (TSC), represents a novel, targeted treatment opportunity to enhance the standard-of-care for conditions associated with hypoxia.